Fluoro-deoxy-glucose positron emission tomography/computed tomography in lymphoma: A pictorial essay

Kuruva, Manohar; Mittal, Bhagwant Rai; Bhattacharya, Anish; Malhotra, Pankaj; Varma, Subhash

doi:10.4103/0972-3919.118256

Cited by 2 publications

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Feasibility of a multimodal 18F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma

et al. 2015

View full text Add to dashboard Cite

Background18F-FDG PET/CT imaging is widely utilized in the clinical evaluation of patients with suspected or documented lymphoma. The aim was to describe our cumulative experience with a multimodal 18F-FDG-directed lymph node surgical excisional biopsy approach in patients with suspected lymphoma.MethodsThirteen patients (mean age 51 (±16;22–76) years), with suspected new or suspected recurrent lymphoma suggested by 18F-FDG-avid lesions seen on prior diagnostic whole-body PET/CT imaging, were injected IV with 18F-FDG prior to undergoing same-day diagnostic lymph node surgical excisional biopsy in the operating room. Various 18F-FDG detection strategies were used on the day of surgery, including, (1) same-day pre-resection patient PET/CT; (2) intraoperative gamma probe assessment; (3) clinical scanner specimen PET/CT imaging of whole surgically excised tissue specimens; (4) specimen gamma well counts; and/or (5) same-day post-resection patient PET/CT.ResultsSame-day 18F-FDG injection dose was 14.8 (±2.4;12.5-20.6) millicuries or 548 (±89;463–762) megabecquerels. Sites of 18F-FDG-avid lesions were 4 inguinal, 3 cervical, 3 abdominal/retroperitoneal, 2 axillary, and 1 gluteal region subcutaneous tissue. Same-day pre-resection patient PET/CT was performed on 6 patients. Intraoperative gamma probe assessment was performed on 13 patients. Clinical scanner PET/CT imaging of whole surgically excised tissue specimens was performed in 10 cases. Specimen gamma well counts were performed in 6 cases. Same-day post-resection patient PET/CT imaging was performed on 8 patients. Time from 18F-FDG injection to same-day pre-resection patient PET/CT, intraoperative gamma probe assessment, and same-day post-resection patient PET/CT were 76 (±8;64–84), 240 (±63;168–304), and 487 (±104;331–599) minutes, respectively. Time from 18F-FDG injection to clinical scanner PET/CT of whole surgically excised tissue specimens was 363 (±60;272–446) minutes. Time from 18F-FDG injection to specimen gamma well counts was 591 (±96;420–689) minutes. Intraoperative gamma probe assessment successfully identified 18F-FDG-avid lesions in 12/13 patients. Histopathologic evaluation confirmed lymphoma in 12/13 patients and benign disease in 1/13 patients.ConclusionsA multimodal approach to 18F-FDG-directed lymph node surgical excisional biopsy for suspected lymphoma is technically feasible for guiding appropriate diagnostic tissue sampling of lymph nodes seen as 18F-FDG-avid lesions on diagnostic 18F-FDG PET/CT imaging.

show abstract

Feasibility of a multimodal 18F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma

et al. 2015

View full text Add to dashboard Cite

show abstract

2-Deoxy-D-Glucose: A Glycolysis Inhibitor in the Treatment of Cancer

Aruna Poorani,

Mohamed Ismail,

Santhoshkumar

et al. 2024

2-Deoxy-D-Glucose: Chemistry and Biology

View full text Add to dashboard Cite

Cancer involves abnormal and rapid cell growth, which requires an increased energy supply for proliferating cells. As the demand for glucose rises in cancer cells, the expression and activity of glucose transporters (GLUTs) also increase to facilitate higher cellular glucose uptake. Cancer cells tend to shift their glucose metabolic pathway from mitochondrial oxidative phosphorylation towards aerobic glycolysis. 2-Deoxy-D-glucose competes with glucose and involves aerobic glycolysis. It leads to the inhibition of HK and PGI, diminishes ATP production, and induces apoptosis. Further, the increase in the AMP/ATP ratio promotes the AMPK signaling, downregulating VEGF, and leading to angiogenesis inhibition and autophagy. As the structural mimic of mannose, 2-DG interferes with the N-linked glycosylation, leading to ER stress, and triggering the mitochondrial apoptotic pathway. 2-DG has been employed as an antiproliferative, antiangiogenic, and antimetastatic drug by being involved in the energy metabolic pathway. Combination therapy shows improved results and reduces chemotherapeutic drug resistance. In this chapter, we will discuss the Warburg effect, the role of 2-DG in the inhibition of aerobic glycolysis, and how 2- DG inhibits the various other cancer hallmarks in energy metabolic pathway. Also, reports on cancer treatment as well as cancer cell-imaging and risks associated with chronic exposure are discussed.

show abstract

Fluoro-deoxy-glucose positron emission tomography/computed tomography in lymphoma: A pictorial essay

Cited by 2 publications

References 14 publications

Feasibility of a multimodal 18F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma

Feasibility of a multimodal 18F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma

2-Deoxy-D-Glucose: A Glycolysis Inhibitor in the Treatment of Cancer

Contact Info

Product

Resources

About